Athira Pharma, Inc. (NASDAQ:LONA) Receives Average Recommendation of “Hold” from Analysts

Shares of Athira Pharma, Inc. (NASDAQ:LONA) have been given a consensus rating of “Hold” by the five analysts that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $15.00.

LONA has been the topic of several recent analyst reports. Cantor Fitzgerald initiated coverage on Athira Pharma in a report on Thursday, February 26th. They set an “overweight” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Athira Pharma in a report on Monday, May 11th. Zacks Research raised Athira Pharma to a “hold” rating in a report on Friday, February 27th. Wall Street Zen raised Athira Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Piper Sandler initiated coverage on Athira Pharma in a report on Wednesday, May 27th. They set an “overweight” rating and a $20.00 target price on the stock.

Athira Pharma Stock Performance

Shares of NASDAQ:LONA opened at $8.18 on Friday. Athira Pharma has a 12 month low of $2.85 and a 12 month high of $14.21. The company has a market capitalization of $76.84 million, a PE ratio of -1.57 and a beta of 1.97. The business’s 50 day moving average price is $9.24.

Athira Pharma (NASDAQ:LONA) last announced its earnings results on Thursday, May 7th. The company reported ($1.73) EPS for the quarter. On average, equities analysts predict that Athira Pharma will post -3.12 earnings per share for the current fiscal year.

About Athira Pharma

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.